STXBP1

Across TCGA pan-cancer cohorts, STXBP1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STXBP1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher STXBP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STXBP1 expression acts as an unfavorable survival marker.

LUSC, SARC, and PRAD are the cancer types where STXBP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.166	0.676	.002	24	view →
SARC	OS	Median	All	0.151	0.730	.004	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	0.136	0.708	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STXBP1–LUSC (OS)

Open the LUSC breakdown →